| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2497 | Hcv Gt2a Inhibitor 5m | Antiviral agent against HCV genotype 2a JFH-1 infected in human Huh7.5.1 cells |
|
| DCC2498 | Hcv-in-5 | Novel Inhibitor of Hepatitis C Virus |
|
| DCC2499 | Hd-800 | High affinity and selective colchicine site tubuline inhibitor amenable to radiolabel with C-11, a positron emitting isotope |
|
| DCC2500 | Hdac6 Degrader 14a | Novel PROTAC HDAC6 degrader, efficiently and selectively decreased HDAC6 levels in several cell lines, including activated THP-1 cells |
|
| DCC2501 | Hdac6 Degrader Np8 | Novel potent and selective PROTAC degrader of HDAC6 protein |
|
| DCC2502 | Hdac6 Inhibitor 6h | Novel hHDAC6 inhibitor, having low inhibitory potency over hHDAC1 and hHDAC8, as potential pharmacological tools for idiopathic pulmonary fibrosis (IPF) treatment |
|
| DCC2503 | Hdac6 Inhibitor Xp5 | Novel potent HDAC6 inhibitor with an IC 50 of 31 nM and excellent HDAC6 selectivity (SI = 338 for HDAC6 over HDAC3), displaying high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC |
|
| DCC2504 | Hdac6-in-10c | Novel HDAC6 isoform-selective inhibitor, increasing the acetylation level of α-tubulin with little effect on the acetylation of histone H3, inducing apoptosis in HL-60 cell by activating caspase 3 |
|
| DCC2505 | Hdac6-in-3f | Potent and selective HDAC6 inhibitor |
|
| DCC2506 | Hdac6-in-4b | Potent and selective HDAC6 inhibitor |
|
| DCC2507 | Hdac6-in-w5 | Novel highly potent and selective HDAC6 inhibitor with an IC 50 of 2.54 nM and being more than 290- to 3300-fold selective over other HDAC isoforms |
|
| DCC2508 | Hdac8 Protac | First-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8) |
|
| DCC2509 | Hdac8-in-8b | Novel Selective Histone Deacetylase 8 (HDAC8) Inhibitor with Anti-Neuroblastoma Activity |
|
| DCC2510 | Hdac-in-6 | Novel HDAC inhibitor, targeting HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9 |
|
| DCC2511 | Hdac-in-h13 | Novel Histone deacetylase (HDAC) inhibotor, displays potent inhibitory activity towards human HDACs and several cancer cells lines |
|
| DCC2512 | Hdl376 Featured | HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC50 = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease. |
|
| DCC2513 | Hdp-mimic C4 | Potent antifungal agent, hosting defense peptide mimic through a membrane-active mechanism |
|
| DCC2514 | Hds029 | Potent inhibitor of the ErbB receptor family (IC50 values are 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2 respectively) |
|
| DCC2515 | Helenalin Acetate | Anti-inflammatory and anti-cancer agent, disrupting the cooperation of CCAAT-box/enhancer-binding protein beta (C/EBPß) and co-activator p300 |
|
| DCC2516 | Helenalin Methacrylate | Natural anti-inflammatory and anti-cancer agent |
|
| DCC2517 | Helioxanthin | Inhibitor of interleukin-1β-induced MIP-1β production |
|
| DCC2518 | Hemiasterlin | Cytotoxic peptide, inducing mitotic arrest and abnormal spindle formation |
|
| DCC2519 | Hemigossypol | The biosynthetic precursor of gossypol |
|
| DCC2520 | Hemisurfen | Heparan sulfate antagonist |
|
| DCC2521 | Heparin Disaccharide I-s Sodium Salt | Heparin derivative for treatment of thrombotic diseases |
|
| DCC2522 | Hepcidin | Master regulator of iron homeostasis, contributing to Swedish mutant APP-induced osteoclastogenesis and trabecular bone loss |
|
| DCC2523 | Hepta-histidine | Novel inhibitor of Tau aggregation against Tau-related neurodegenerative diseases including Alzheimer's disease (AD) |
|
| DCC2524 | Het-dpd-13a | Novel LsrK inhibitor (ID 50 119 μM) agaist antimicrobial resistance (AMR) |
|
| DCC2525 | Heterotaxin | Novel TGF-β Signaling Inhibitor |
|
| DCC2526 | Hetrombopag Olamine | Novel orally bioavailable, non-peptide thrombopoietin (TPO) receptor agonist |
|
